Filed 0//20/25 Case 24-80040-sgi11 Doc 829 Entered 01/20/25 23:17:1 Docket #0829 Date Filed: 04/20/2025 Imaged Certificate or Nouce ст 01 т<u>0</u>



CLERK, U.S. BANKRUPTCY COURT NORTHERN DISTRICT OF TEXAS

ТЕКІ THE DATE OF ENTRY IS ON THE COURT'S DOCKET

The following constitutes the ruling of the court and has the force and effect therein described.

Signed April 18, 2025

United States Bankruptcy Judge

IN THE UNITED STATES BANKRUPTCY COURT NORTHERN DISTRICT OF TEXAS **DALLAS DIVISION**

§

§

In re:

EIGER BIOPHARMACEUTICALS, INC., et al.,¹

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

ORDER (I) SETTING DISCOVERY AND BRIEFING SCHEDULE AND (II) ON RELATED ITEMS

At the Status Conference Hearing held before the Court on April 15, 2025, to consider

the following matters:

(A) Objection and Response of the Liquidating Trustee and Plan Administrator to Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc. [Docket No. 777 (redacted); Docket No. 784 (sealed)] ("Administrative Expense Objection") filed by Dundon Advisors, LLC, c/o Joshua Nahas, in its capacity as liquidating trustee (the "Liquidating Trustee") of the liquidating trust of Eiger BioPharmaceuticals, Inc., et al (the "Debtors" or "Eiger") and the Plan Administrator ("Plan Administrator") appointed pursuant to the Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc and its Debtor Affiliates, to



¹ The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Ave., Dallas, Texas 75201.

Case 24-80040-sgj11 Doc 829 Filed 04/20/25 Entered 04/20/25 23:17:17 Desc Imaged Certificate of Notice Page 2 of 10

the *Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc.* [Docket No. 729] (the "<u>Administrative Expense Motion</u>") filed by Sentynl Therapeutics, Inc. ("<u>Sentynl</u>");

(C) Sentynl Therapeutics, Inc.'s Motion (I) to Enforce the Zokinvy Sale Order and (II) for Contempt Against Eiger Innotherapeutics, Inc. [Docket No. 779/781] (the "<u>Sentynl Motion to</u> <u>Enforce</u>") filed by Sentynl; and

(D) EIT Pharma, Inc., Formerly Known as Eiger InnoTherapeutics, Inc.'s Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order [Docket No. 787] ("EIT Motion") filed by EIT Pharma, Inc ("EIT")

(together, the Administrative Expense Objection, the Administrative Expense Motion, Sentynl

Motion to Enforce and the EIT Motion, the "Contested Matters") (together, Sentynl, the

Progeria Research Foundation ("PRF"), the Liquidating Trustee, the Plan Administrator, and

EIT, the "Parties"); this Court having jurisdiction to consider the Contested Matters pursuant to

28 U.S.C. § 1334; and venue being proper before this Court pursuant to 28 U.S.C. §§ 1408 and

1409; and this Court having heard the arguments of counsel and their agreement to continue to

have the Court handle the Contested Matters as motion practice rather than adversary

proceedings, after due deliberation and sufficient cause appearing therefor.

IT IS HEREBY ORDERED THAT

1. Based on the agreement of the Parties, the Contested Matters shall proceed as

contested matters under F. R. Bankr. P. 9014.

- 2. Mediation shall involve all Contested Matters.
- 3. The Parties may not conduct more than 1 deposition of any witness, and the

deposition shall not exceed 7 hours², without the consent of all Parties.

4. The following dates and deadlines for the Contested Matters are hereby approved:

 $^{^{2}}$ To the extent a witness is being deposed individually and as a 30(b)(6) representative, only 1 7-hour deposition will be allowed of such individual.

Timeline and Briefing Schedule			
Dates	Administrative Expense Claim and Administrative Expense Objection	Sentynl Motion to Enforce	EIT Motion
April 2, 2025	Deadline to serve deposition notices and discovery		
April 11, 2025		EIT initial deadline to respond to Sentynl Motion	Sentynl Response to EIT Motion
April 15, 2025	S	Status Conference Hearin	g
April 16, 2025	Deadline to serve deposition notices and discovery		
April 21, 2025	Deadli	ne to file any pre-hearing n	notions
April 25, 2025	Deadline to respond to any pre-hearing motions		
April 21- May 9, 2025	Depositions of witnesses (subject to scheduling)		
April 29, 2025 at 9:30am	Hearing on pre-hearing motions and status conference re discovery		
May 9, 2025	Discovery deadline		
May 12, 2025	Meet and confer		
May 15, 2025	Sentynl Deadline to file supplemental/amended response to LT's Objection		
May 16, 2025	5	Mediation in Dallas ³	
May 16, 2025		EIT Deadline to file supplemental/amended response to Sentynl Motion	
May 20, 2025		Deadline for Sentynl to file reply in support of Sentynl Motion	
May 21, 2025	Deadline for LT to file reply in support of LT's Objection		
May 23, 2025 at 4:00 CT	Witness & exhibit lists deadline		

 $^{^{3}}$ The Parties together with the mediator may agree to a different date and location for the mediation.

Case 24-80040-sgj11 Doc 829 Filed 04/20/25 Entered 04/20/25 23:17:17 Desc Imaged Certificate of Notice Page 4 of 10

May 28, 2025 at 9:30am and May 29, 2025 at 9:30am	t 9:30am nd Evidentiary Hearing ay 29, 2025
---	---

5. The Parties may modify the deadlines by agreement of all Parties; provided that, the Parties will seek Court approval to modify any hearing date set by the Court.

6. As set forth above, the court has ordered the Parties to mediate by May 16, 2025. The court has directed that the parties shall select a mutually agreeable **private** mediator or, in the event they cannot find a mutually agreeable **private** mediator, the Parties shall notify the courtroom deputy and this court will select a mediator. The mediator's fees will be paid split equally among all Parties except PRF. The mediator shall not be required to file fee applications and seek court approval of the fees and expenses. A Party representative with decision making authority and counsel for each party shall be present at the mediation. As in all settlement matters, all settlement negotiations conducted during the mediation are confidential and privileged and may not be used at any trial or hearing in the bankruptcy case. The mediator is directed to keep all information from the mediation, except that the mediator may report to this court as to whether a settlement was or was not reached. Except as herein provided, mediation shall be pursuant to Section Q of the Procedures for Complex Cases in the Northern District of Texas

The terms of this Order shall supersede the *Joint Stipulation and Agreed Order* [Docket No. 803] entered on April 9, 2025.

END OF ORDER # #

Case 24-80040-sgj11 Doc 829 Filed 04/20/25 Entered 04/20/25 23:17:17 Desc Imaged Certificate of Notice Page 5 of 10 Case 24-80040-sgj11 Doc 829 Filed 04/20/25 Entered 04/20/25 23:17:17 Desc

Imaged Certificate of Notice Page

ce Page 6 of 10

United States Bankruptcy Court

Northern District of Texas

In re:

Eiger BioPharmaceuticals, Inc.

Debtor

District/off: 0539-8

CERTIFICATE OF NOTICE

User: admin

Date Rcvd: Apr 18, 2025

Form ID: pdf012

Page 1 of 5 Total Noticed: 1

The following symbols are used throughout this certificate:

Symbol Definition

+

Addresses marked '+' were corrected by inserting the ZIP, adding the last four digits to complete the zip +4, or replacing an incorrect ZIP. USPS regulations require that automation-compatible mail display the correct ZIP.

Notice by first class mail was sent to the following persons/entities by the Bankruptcy Noticing Center on Apr 20, 2025:

Recip ID	Recipient Name and Address
aty	+ Andrew J. Townsell, Sidley Austin LLP, 787 7th Avenue, New York, NY 10019-6088

TOTAL: 1

Notice by electronic transmission was sent to the following persons/entities by the Bankruptcy Noticing Center. Electronic transmission includes sending notices via email (Email/text and Email/PDF), and electronic data interchange (EDI). NONE

BYPASSED RECIPIENTS

The following addresses were not sent this bankruptcy notice due to an undeliverable address, *duplicate of an address listed above, *P duplicate of a preferred address, or ## out of date forwarding orders with USPS.

NOTICE CERTIFICATION

I, Gustava Winters, declare under the penalty of perjury that I have sent the attached document to the above listed entities in the manner shown, and prepared the Certificate of Notice and that it is true and correct to the best of my information and belief.

Meeting of Creditor Notices only (Official Form 309): Pursuant to Fed .R. Bank. P.2002(a)(1), a notice containing the complete Social Security Number (SSN) of the debtor(s) was furnished to all parties listed. This official court copy contains the redacted SSN as required by the bankruptcy rules and the Judiciary's privacy policies.

Date: Apr 20, 2025

Signature:

/s/Gustava Winters

CM/ECF NOTICE OF ELECTRONIC FILING

The following persons/entities were sent notice through the court's CM/ECF electronic mail (Email) system on April 18, 2025 at the address(es) listed below:		
Name	Email Address	
Anne G. Wallice	on behalf of Debtor Eiger BioPharmaceuticals Inc. anne.wallice@sidley.com, annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com	
Anne G. Wallice	on behalf of Debtor EBPI Merger Inc. anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com	
Anne G. Wallice	on behalf of Jointly Administered Party/Debtor EB Pharma LLC anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com	
Anne G. Wallice	on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com	
Anne G. Wallice	on behalf of Debtor EB Pharma LLC anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com	

Case No. 24-80040-sgj

Chapter 11

Case 24-80040-sgj	11 Doc 829 Filed 04/20/25 Imaged Certificate of Notice		Desc
District/off: 0539-8	User: admin	5	Page 2 of 5
Date Rcvd: Apr 18, 2025	Form ID: pdf012		Total Noticed: 1
Anne G. Wallice			

Anne G. Wallice	on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallice	on behalf of Debtor Eiger BioPharmaceuticals Europe Limited anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallice	on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallice	on behalf of Debtor EigerBio Europe Limited anne.wallice@sidley.com annewallice4789@ecf.pacerpro.com;nyefiling@sidley.com
Beverly Weiss Manne	on behalf of Creditor Thermo Fisher Scientific et al. bmanne@tuckerlaw.com, bewmanne@aol.com;npetroy@tuckerlaw.com
Bruce H White	on behalf of Creditor Dr. Colleen Craig Kaludzinski bwhite@parsonsbehle.com
Candice Marie Carson	on behalf of Creditor Eton Pharmaceuticals Inc. Candice.Carson@butlersnow.com
Daniel N. Gonzalez	on behalf of Creditor Committee Official Unsecured Creditors Committee dgonzalez@melandbudwick.com ltannenbaum@melandbudwick.com;ltannenbaum@ecf.courtdrive.com;mrbnefs@yahoo.com
David E. Sklar	on behalf of Interested Party Official Equity Security Holders' Committee desklar@pbnlaw.com mpdermatis@pbnlaw.com;jmoconnor@pbnlaw.com
David R. Eastlake	on behalf of Creditor Oxford Finance LLC David.Eastlake@gtlaw.com
Dawn Whalen Theiss	on behalf of Creditor United States Of America Internal Revenue Service dawn.theiss@usdoj.gov brooke.lewis@usdoj.gov;CaseView.ECF@usdoj.gov
Duston K. McFaul	on behalf of Debtor Eiger BioPharmaceuticals Inc. dmcfaul@sidley.com, txefilingnotice@sidley.com;efilingnotice@sidley.com;mgburke@sidley.com;apropps@sidley.com;asoler@sidley.com;thomas.ma ck@sidley.com;emcdonnell@sidley.com
Elizabeth Ziegler Young	on behalf of U.S. Trustee United States Trustee elizabeth.a.young@usdoj.gov
Eric M. Van Horn	on behalf of Creditor Merck Sharp & Dohme LLC ericvanhorn@spencerfane.com
Garrick Chase Smith	on behalf of Attorney Munsch Hardt Kopf & Harr P.C. gsmith@munsch.com
Garrick Chase Smith	on behalf of Creditor Committee Official Unsecured Creditors Committee gsmith@munsch.com
Garrick Chase Smith	on behalf of Attorney Meland Budwick P.A. gsmith@munsch.com
George H. Barber	on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP gbarber@bradley.com, sbyrd@bradley.com;gbarberbradley@ecf.courtdrive.com;george-barber-8068@ecf.pacerpro.com
Hugh M. Ray, III	on behalf of Interested Party Sentynl Therapeutics Inc. hugh.ray@pillsburylaw.com, bankruptcee@yahoo.com;nancy.jones@pillsburylaw.com;docket@pillsburylaw.com
J. Machir Stull	on behalf of Creditor IQVIA Inc. mstull@jw.com, osalvatierra@jw.com;kgradney@jw.com
Jason S. Brookner	on behalf of Interested Party EIT Pharma Inc., formerly known as Eiger InnoTherapeutics, Inc. jbrookner@grayreed.com, lwebb@grayreed.com;acarson@grayreed.com
Jason S. Brookner	on behalf of Interested Party Eiger InnoTherapeutics Inc. jbrookner@grayreed.com, lwebb@grayreed.com;acarson@grayreed.com
Jason S. Brookner	on behalf of Creditor Jeffrey S. Glenn Individually jbrookner@grayreed.com, lwebb@grayreed.com;acarson@grayreed.com
Jay Robert Bender	

Case 24 800	40 ari11 Dec 020 Filed 04/20/25 Entered 04/20/25 22:17:17	Deee	
Case 24-8004	40-sgj11 Doc 829 Filed 04/20/25 Entered 04/20/25 23:17:17 Imaged Certificate of Notice Page 8 of 10	Desc	
District/off: 0539-8	User: admin	Page 3 of 5	
Date Rcvd: Apr 18, 2025	Form ID: pdf012	Total Noticed: 1	
	on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP jbender@bradley.com		
Jeff P. Prostok	on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP jeff.prostok@vhh.law, jprostok@ecf.courtdrive.com;khartogh@ecf.courtdrive.com;forsheyprostokllp@jubileebk.net;kristina.hartogh@vhh.law;bankrupt cy.docketing@vhh.law;bankruptcy.docketing@ecf.courtdrive.com		
John D. Gaither	on behalf of Spec. Counsel Neligan LLP jgaither@neliganlaw.com cperkins@neliganlaw.com;kplumlee@neliganlaw.com	ieliganlaw.com	
John James Sparacino	on behalf of Interested Party Official Equity Security Holders' Committee jsparacino@mckoolsmith.com john-sparacino-7086@ecf.pacerpro.com;managingclerk@mckoolsmith.com;scastillo@mckoolsmith.com		
John Joseph Kuster	on behalf of Jointly Administered Party/Debtor EB Pharma LLC jkuster@sidley.com		
John Joseph Kuster	on behalf of Interested Party Eiger InnoTherapeutics Inc. jkuster@sidley.com		
John Joseph Kuster	on behalf of Debtor Eiger BioPharmaceuticals Inc. jkuster@sidley.com		
John Joseph Kuster	on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited jkuster@sidley.com		
John Joseph Kuster	on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited jkuster@sidley.c	om	
John Joseph Kuster			

- on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. jkuster@sidley.com
 - on behalf of Creditor Texas Comptroller of Public Accounts Revenue Accounting Division bk-jstern@oag.texas.gov, sherri.simpson@oag.texas.gov
 - on behalf of Creditor Merck Sharp & Dohme LLC jdunn@cov.com
- Kendal B. Reed on behalf of Creditor Biorasi LLC kreed@condontobin.com, atobin@condontobin.com;cnavarro@condontobin.com;emensch@condontobin.com Kyle Woodard
- on behalf of Creditor Thermo Fisher Scientific et al. kwoodard@krcl.com, KWoodard@ecf.courtdrive.com;ecf@krcl.com Lawrence James Dickinson
 - on behalf of Interested Party Sentynl Therapeutics Inc. james.dickinson@pillsburylaw.com, nancy.jones@pillsburylaw.com;docket@pillsburylaw.com
 - on behalf of Interested Party Sentynl Therapeutics Inc. mark@strombergstock.com, deanna@strombergstock.com;admin@strombergstock.com
 - on behalf of Creditor Eton Pharmaceuticals Inc. martin.sosland@butlersnow.com, ecf.notices@butlersnow.com,velvet.johnson@butlersnow.com
 - on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited nelner@sidley.com
- Nathan Elner on behalf of Debtor EigerBio Europe Limited nelner@sidley.com
- Nathan Elner on behalf of Debtor Eiger BioPharmaceuticals Inc. nelner@sidley.com
- Nathan Elner on behalf of Debtor Eiger BioPharmaceuticals Europe Limited nelner@sidley.com
- Nathan Elner on behalf of Jointly Administered Party/Debtor EB Pharma LLC nelner@sidley.com
- Nathan Elner on behalf of Debtor EB Pharma LLC nelner@sidley.com
- Nathan Elner on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited nelner@sidley.com

on behalf of Debtor EBPI Merger Inc. nelner@sidley.com

Nathan Elner

John Mark Stern

Joseph R. Dunn

Mark Stromberg

Martin A. Sosland

Nathan Elner

Nathan Elner

Case 24-80040-sgi11 Doc 829 Filed 04/20/25 Entered 04/20/25 23:17:17 Desc Imaged Certificate of Notice Page 9 of 10 District/off: 0539-8 User: admin Page 4 of 5 Total Noticed: 1 Date Rcvd: Apr 18, 2025 Form ID: pdf012 on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. nelner@sidley.com Patrick J. Neligan, Jr. on behalf of Debtor Eiger BioPharmaceuticals Inc. pneligan@neliganlaw.com, rclark@neliganlaw.com;jgaither@neliganlaw.com;cperkins@neliganlaw.com;rclark@ecf.courtdrive.com Phillip L. Lamberson on behalf of Creditor Amylyx Pharmaceuticals Inc. plamberson@winstead.com

on behalf of Interested Party Sentynl Therapeutics Inc. reed.trechter@pillsburylaw.com

scastillo@mckoolsmith.com

scastillo@mckoolsmith.com

on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP rjones@bradley.com

on behalf of Interested Party Official Equity Security Holders' Committee mvenus@mckoolsmith.com

on behalf of Creditor Oracle America Inc. schristianson@buchalter.com, cmcintire@buchalter.com

on behalf of Creditor Committee Official Unsecured Creditors Committee tberghman@munsch.com

amays@munsch.com,CourtMail@munsch.com;hvalentine@munsch.com

nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

on behalf of Jointly Administered Party/Debtor EB Pharma LLC tom.califano@sidley.com nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. tom.califano@sidley.com nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited tom.califano@sidley.com nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

ny efiling @sidley.com; tom-califano-6649 @ecf.pacerpro.com; emcdonnell@sidley.com

nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

on behalf of Other Professional Alvarez & Marsal North America LLC tom.califano@sidley.com nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

on behalf of Creditor Fujifilm Diosynth Biotechnologies U.S.A., Inc. tggreen@polsinelli.com,

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited tom.califano@sidley.com

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited tom.califano@sidley.com

on behalf of Debtor Eiger BioPharmaceuticals Inc. tom.califano@sidley.com, nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

on behalf of Debtor EBPI Merger Inc. tom.califano@sidley.com

on behalf of Debtor EB Pharma LLC tom.califano@sidley.com

on behalf of Debtor EigerBio Europe Limited tom.califano@sidley.com

docketing@polsinelli.com;robrien@polsinelli.com;bvogt@polsinelli.com

ustpregion06.da.ecf@usdoj.gov

on behalf of Interested Party Dundon Advisers LLC, as Eiger Liquidating Trustee mvenus@mckoolsmith.com,

- Reed Trechter
- Roger G. Jones
- S. Margie Venus
- U
- S. Margie Venus
- Shawn M. Christianson
- Thomas Daniel Berghman

- Thomas Robert Califano

- Thomas Robert Califano
- Thomas Robert Califano
- Thomas Robert Califano
- Thomas Robert Califano
- Thomas Rooort Cullian
- Thomas Robert Califano
- Thomas Robert Califano
- Thomas Robert Califano
- Thomas Robert Califano
-
- Thomas Robert Califano
- Trinitee G. Green
- United States Trustee
- Veronica A. Courtney
 - veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com
- Veronica A. Courtney
- on behalf of Jointly Administered Party/Debtor EB Pharma LLC vcourtney@sidley.com

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. vcourtney@sidley.com

Case 24-800	40-sgj11 Doc 829 Filed 04/ Imaged Certificate of N		2:17 Desc
District/off: 0539-8	User: admi	0	Page 5 of 5
Date Rcvd: Apr 18, 2025	Form ID: p		Total Noticed: 1
<u>r</u> , , , , ,	veronicacourtney6476@ecf.pacerpro.com;txe		
	veronicacouriney0470@eci.pacerpro.com,ixe	minghotice@statey.com	
Veronica A. Courtney	on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited vcourtney@sidley.com veronicacourtney6476@ecf.pacerpro.com;txefilingnotice@sidley.com		
Veronica A. Courtney	on behalf of Debtor EB Pharma LLC vcourtney@ veronicacourtney6476@ecf.pacerpro.com;txe		
Veronica A. Courtney	on behalf of Debtor Eiger BioPharmaceuticals Eu veronicacourtney6476@ecf.pacerpro.com;txe		
Veronica A. Courtney	on behalf of Debtor EigerBio Europe Limited vcd veronicacourtney6476@ecf.pacerpro.com;txe		
Veronica A. Courtney	on behalf of Debtor EBPI Merger Inc. vcourtney veronicacourtney6476@ecf.pacerpro.com;txe		
Veronica A. Courtney	on behalf of Jointly Administered Party/Debtor E veronicacourtney6476@ecf.pacerpro.com;txe	iger BioPharmaceuticals Europe Limited vcourtney filingnotice@sidley.com	@sidley.com
Veronica A. Courtney	on behalf of Debtor Eiger BioPharmaceuticals Ir veronicacourtney6476@ecf.pacerpro.com;txe		
Warren J. Martin, Jr	on behalf of Interested Party Official Equity Secu	rity Holders' Committee wjmartin@pbnlaw.com	
William E Curtin	on behalf of Debtor EigerBio Europe Limited wc william-curtin-5829@ecf.pacerpro.com;nyefiling		
William E Curtin	on behalf of Debtor Eiger BioPharmaceuticals Eu william-curtin-5829@ecf.pacerpro.com;nyefiling		
William E Curtin	on behalf of Debtor Eiger BioPharmaceuticals Ir william-curtin-5829@ecf.pacerpro.com;nyefiling		
William E Curtin	on behalf of Jointly Administered Party/Debtor E william-curtin-5829@ecf.pacerpro.com;nyefiling		
William E Curtin	on behalf of Jointly Administered Party/Debtor E william-curtin-5829@ecf.pacerpro.com;nyefiling		
William E Curtin	on behalf of Debtor EB Pharma LLC wcurtin@si	dley.com william-curtin-5829@ecf.pacerpro.com;r	yefiling@sidley.com
William E Curtin	on behalf of Jointly Administered Party/Debtor E william-curtin-5829@ecf.pacerpro.com;nyefiling		
William E Curtin	on behalf of Debtor EBPI Merger Inc. wcurtin@s	idley.com william-curtin-5829@ecf.pacerpro.com;	nyefiling@sidley.com
William E Curtin	on behalf of Jointly Administered Party/Debtor E william-curtin-5829@ecf.pacerpro.com;nyefiling	iger BioPharmaceuticals Europe Limited wcurtin@ @sidley.com	sidley.com

TOTAL: 93